発現ベクター市場- 世界の産業規模、シェア、動向、機会、予測、ホストタイプ別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

世界の発現ベクター市場は、2024年に4億4,050万米ドルと評価され、2030年までのCAGRは5.10%で、予測期間中に目覚ましい成長を遂げると予測されています。

発現ベクターは、バイオテクノロジーや分子生物学において、宿主細胞内で特定の遺伝子を運び発現させるために使用されるDNA分子の一種です。発現ベクターは、それが運ぶ遺伝子からタンパク質または他の遺伝子産物の生産を容易にするように設計されています。外来遺伝物質（例えば、目的の遺伝子）を宿主細胞に導入するための分子ビヒクルとして機能し、そこで遺伝子が転写され、翻訳されて機能的タンパク質を産生することができます。発現ベクターは、遺伝子の転写を開始するスイッチとして働く特定のDNA配列であるプロモーター領域を含んでいます。

市場概要
予測期間	2026-2030
市場規模：2024年	4億4,050万米ドル
市場規模：2030年	5億8,884万米ドル
CAGR：2025年～2030年	5.10%
急成長セグメント	治療薬
最大市場	北米

プロモーターはその強度と特異性に基づいて選択されることが多く、目的とする遺伝子発現レベルや宿主細胞の種類によって異なります。発現ベクターには複製起点があり、これは宿主細胞の複製装置によって認識されるDNA配列です。この配列により、ベクターは宿主細胞内で複製・増殖し、導入された遺伝子が細胞分裂中に娘細胞に確実に受け継がれます。

主な市場促進要因

遺伝子治療の拡大

主な市場課題

安全性への懸念

主要市場動向

環境の持続可能性

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の発現ベクター市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • ホストタイプ別（細菌発現ベクター、哺乳類発現ベクター、昆虫発現ベクター、酵母発現ベクター、その他）
  • 用途別（治療、調査、その他）
  • エンドユーザー別（製薬・バイオテクノロジー、学術調査、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の発現ベクター市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の発現ベクター市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の発現ベクター市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の発現ベクター市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの発現ベクター市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の発現ベクター市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Thermo Fisher Scientific, Inc.
• Promega Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Merck KGaA
• TAKARA HOLDINGS Inc.
• GenScript Corp.
• Quest Diagnostics Inc.
• Addgene, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Expression Vector Market was valued at USD 440.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.10% through 2030. An expression vector is a type of DNA molecule used in biotechnology and molecular biology to carry and express specific genes within host cells. Expression vectors are designed to facilitate the production of proteins or other gene products from the genes they carry. They serve as molecular vehicles for introducing foreign genetic material (e.g., a gene of interest) into host cells, where the gene can be transcribed and translated to produce a functional protein. Expression vectors contain a promoter region, which is a specific DNA sequence that acts as a switch to initiate gene transcription.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 440.50 Million
Market Size 2030	USD 588.84 Million
CAGR 2025-2030	5.10%
Fastest Growing Segment	Therapeutics
Largest Market	North America

Promoters are often chosen based on their strength and specificity, depending on the desired level of gene expression and the type of host cell. Expression vectors have an origin of replication, which is a DNA sequence recognized by the host cell's replication machinery. This sequence allows the vector to replicate and propagate inside the host cell, ensuring that the introduced gene is passed on to daughter cells during cell division.

Key Market Drivers

Gene Therapy Expansion

Expression vectors serve as crucial gene delivery vehicles in gene therapy. They are used to transport therapeutic genes into target cells, facilitating the correction of genetic defects or the introduction of therapeutic genes to treat various diseases. Gene therapy has expanded beyond rare diseases to include a wide range of therapeutic applications, such as cancer treatment, genetic disorders, neurological diseases, and cardiovascular conditions. Each application may require tailored expression vectors to achieve optimal gene delivery and expression. The increasing number of gene therapy clinical trials and the approval of gene therapies by regulatory agencies drive demand for expression vectors. These vectors are essential for producing therapeutic genes used in clinical studies and commercialized treatments. Gene therapy research often demands customized expression vectors. Researchers and biotech companies may require vectors that are specific to their therapeutic targets, ensuring precise gene delivery and appropriate expression levels. Many gene therapies rely on viral vectors, such as adeno-associated virus (AAV) vectors and lentiviral vectors, for gene delivery. The development and commercialization of viral vector-based gene therapies have led to a surge in demand for these vectors. For instance, according to the World Health Organization (WHO) in 2021, non-communicable diseases (NCDs) account for 41 million deaths annually, representing 71% of all global deaths. Over 15 million people aged 30 to 69 die each year from NCDs, highlighting their significant impact on public health worldwide.

Key Market Challenges

Safety Concerns

Expression vectors, particularly those used in gene therapy and biopharmaceutical production, must adhere to strict biosafety regulations. Ensuring that vectors do not pose risks to human health, or the environment is essential. Biosafety levels and containment measures are established to prevent accidental release or exposure to genetically modified organisms (GMOs) and biohazardous materials. The use of expression vectors for gene editing, such as CRISPR-Cas9 technology, raises concerns about off-target effects and unintended genetic modifications. Ensuring the precision and safety of gene editing procedures is a critical challenge. The release of genetically modified organisms into the environment, even unintentionally, can have ecological consequences. Proper containment and disposal methods are necessary to prevent environmental contamination. In gene therapy, the integration of expression vectors into the host genome may pose long-term safety risks. Insertional mutagenesis, where vector integration disrupts normal gene function, is a concern. In biopharmaceuticals, the presence of vector-related proteins or antigens in therapeutic products can trigger an immune response in patients, leading to safety issues and reduced efficacy. Achieving tissue-specific expression using expression vectors is challenging but critical for minimizing off-target effects and ensuring safety in gene therapy applications. Viral vectors used in gene therapy can trigger immune responses in patients. Strategies to mitigate vector immunogenicity are essential to improve safety and therapeutic efficacy.

Key Market Trends

Environmental Sustainability

Biotechnology companies are increasingly adopting green bioprocessing practices that reduce the environmental impact of expression vector production. This includes optimizing fermentation processes to minimize waste, energy consumption, and resource use. There is a growing demand for expression vector systems that are environmentally friendly. Companies are developing vector systems that use fewer resources and generate less waste during production. Research and development efforts are focused on creating biodegradable vectors that break down naturally after use, reducing the environmental burden of vector disposal. Companies are exploring sustainable sourcing of raw materials used in vector production, such as growth media components, to reduce the environmental footprint of vector manufacturing. Investments in energy-efficient biomanufacturing processes and facilities are becoming more common. This reduces energy consumption during vector production and contributes to sustainability goals. Sustainable practices aim to minimize waste generation throughout the vector production process. This includes recycling and reusing materials when possible. Companies are taking steps to measure and reduce the carbon footprint associated with vector production and distribution. This may involve using renewable energy sources and optimizing transportation logistics.

Key Market Players

• Thermo Fisher Scientific, Inc.,
  • Promega Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Merck KGaA
• TAKARA HOLDINGS Inc.
• GenScript Corp.
• Quest Diagnostics
• Addgene, Inc.

Report Scope:

In this report, the Global Expression Vector Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Expression Vector Market, By Host Type:

• Bacterial expression vectors
• Mammalian expression vectors
• Insect expression vectors
• Yeast expression vector
• Others

Expression Vector Market, By Application:

• Therapeutic
• Research
• Others

Expression Vector Market, By End-User:

• Pharmaceutical & biotech
• Academic research
• Others

Expression Vector Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Expression Vector Market.

Available Customizations:

Global Expression Vector Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Expression Vector Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Host Type (Bacterial expression vectors, Mammalian expression vectors, Insect expression vectors, Yeast expression vector, Others)
  • 5.2.2. By Application (Therapeutic, Research, Others)
  • 5.2.3. By End User (Pharmaceutical & biotech, Academic research, Others),
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Expression Vector Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Host Type
  • 6.2.2. By Application
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Expression Vector Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Host Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. India Expression Vector Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Host Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Australia Expression Vector Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Host Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User
  • 6.3.4. Japan Expression Vector Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Host Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End-User
  • 6.3.5. South Korea Expression Vector Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Host Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End-User

7. Europe Expression Vector Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Host Type
  • 7.2.2. By Application
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Expression Vector Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Host Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. Germany Expression Vector Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Host Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. Spain Expression Vector Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Host Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Expression Vector Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Host Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. United Kingdom Expression Vector Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Host Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. North America Expression Vector Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Host Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Expression Vector Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Host Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. Mexico Expression Vector Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Host Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. Canada Expression Vector Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Host Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User

9. South America Expression Vector Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Host Type
  • 9.2.2. By Application
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Expression Vector Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Host Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Expression Vector Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Host Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Expression Vector Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Host Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Expression Vector Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Host Type
  • 10.2.2. By Application
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Expression Vector Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Host Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Expression Vector Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Host Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Expression Vector Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Host Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Expression Vector Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Thermo Fisher Scientific, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Promega Corporation
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Agilent Technologies, Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Bio-Rad Laboratories Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. QIAGEN NV
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Merck KGaA
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. TAKARA HOLDINGS Inc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. GenScript Corp.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Quest Diagnostics Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Addgene, Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer